The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and the Calreticulin (CALR) mutations are mutually exclusive in essential thrombocythemia and support a novel molecular categorization of essential thrombocythemia. CALR mutations account for approximately 30 % of essential thrombocythemia cases. In a retrospective study, we have examined
Introduction
The JAK2 V617F mutation is found in about 50-60% of essential thrombocythemia (ET) cases while 5-10 % of JAK2 V617F negative ET patients carry a W515K/L gain-of-function mutation in exon 10 of MPL, the thrombopoietin receptor gene [1] [2] [3] [4] [5] .
Recently, indels in CALR have been described in about 70% of JAK2/MPL wild type (double negative) ET and primary myelofibrosis (PMF), in a mutually exclusive pattern with JAK2 and MPL mutations. CALR mutations were not found in other myeloid malignancies, with the exception of MDS-RARS-T 6, 7 . CALR indels are variable but all cause a +1 frameshift leading to a novel Cterminal lacking the KDEL endoplasmic reticulum targeting sequence. CALR mutations have also been identified in familial cases of ET (11%) and PMF (30%) 8 .
Several recent studies have analyzed the clinical and hematological features of ET or PMF patients according to their mutational genotype 6, 7, [9] [10] [11] [12] [13] . These studies have shown that mutant CALR is associated with younger age, higher platelet counts, lower erythrocyte counts, lower leukocyte counts, and lower hemoglobin level compared with JAK2 mutated patients. In addition, in most of these studies CALR mutations were linked to male gender. However, their impact on overall survival seems to differ between ET and PMF.
We retrospectively analyzed a Belgian cohort of 103 JAK2 V617F negative ET patients for the presence of MPL and CALR mutations. In addition, we have compared the clinical and hematological phenotype of CALR mutant cases with a control cohort of 57 JAK2 V617F positive ET, as well as with a group of triple negative ( JAK2 V617F negative, MPL W515 K/L negative, and CALR mutant negative) ET.
Methods

Patients and clinical information:
The study was approved by the local ethical committee of UZ Leuven (study S53745). All patients selected for this study were seen at hematology units of academic or large regional Belgian hospitals , and the availability of stored bone marrow or peripheral blood for molecular analysis. Given that an initial bone marrow biopsy was not available for all cases, the presence of any two minor criteria for PMF (WHO 2008) was an exclusion criterion for this study, if no bone marrow biopsy was available, thus eliminating all cases with potential PMF. First, a cohort of 103 JAK2 V617F negative ET cases diagnosed between 1980 and 2013 at several Belgian hospitals was collected and analyzed for CALR and MPL mutations. We also collected a control cohort of 57 JAK2 V617F positive ET diagnosed between 1987 and 2009 in the University Hospitals Leuven. The median follow-up of the whole cohort of 160 patients was 8 years with a range of 1-34 years. Hematological parameters (platelet counts, erythrocyte counts, leukocyte counts, hemoglobin, and hematocrit) at diagnosis were retrieved as well as cardiovascular events and complications (arterial thrombosis, and venous events). During follow-up, progression to MF, progression to AML, and need for cytoreductive treatment, and splenomegaly were recorded.
Sequencing:
Genomic DNA was extracted from stored bone marrow or blood samples, and analyzed for the JAK2 V617F mutation by allele specific PCR test 1 . The mutational load of JAK2 V617F was determined with the Ipsogen JAK2 MutaQuant Kit (Qiagen, Netherlands). JAK2 V617F negative patients were sequenced for the MPL W515 K/L mutations. For the detection of MPL exon 10 or CALR exon 9 mutations, we used PCR amplification and Sanger sequencing using previously described primers 6 . JAK2 V617F positive and double negative ET patients were sequenced for CALR indels. Sequencing was done on the ABI PRISM® 3100 Genetic Analyzer and the obtained sequencing traces were analyzed on CLC Main Workbench 6 (CLC bio, Denmark). Indels in CALR were labeled in accordance with the study by Klampfl et al. 6 .
Statistics:
The non-parametric Mann-Whitney test was used for the numerical comparisons while the chisquare test or Fisher's exact test were used for nominal comparisons. The analyses were two-tailed, and significance was set at p<0.05. Overall survival, leukemia-free survival, and myelofibrosis-free survival were estimated by Kaplan-Meier test and compared using the log-rank test. The statistical analysis was executed on the SPSS software (version 20).
Results and discussion
First, the JAK2 V617F negative group of patients (n=103) diagnosed since 1980 was sequenced for MPL W515K/L mutations and CALR indels. Sequencing revealed 62 CALR mutations, 12 MPL W515K/L mutations and no MPL or CALR mutations in 33 patients (Figure 1) . Therefore, 63.7% of JAK2 V617F and MPLW515K/L negative patients were carrying an indel in CALR, which is in line with previously reported percentages indicating that CALR mutation percentage in this group is ≥ 50% making CALR the second most recurrently mutated gene in ET 6, 7, 9, 12 . For the comparison of the hematological and clinical phenotype, we selected 57 JAK2 V617F positive patients from our internal database diagnosed since 1987. In contrast with the first published results stating that JAK2 V617F and CALR mutations are mutually exclusive 6, 7 , we identified one JAK2 V617F ET patient with a Type 2 CALR indel who was excluded from further statistical analysis. This is, to the best of our knowledge, the fourth ET patient to be reported with both a CALR mutation and a JAK2 V617F mutation. This combination has so far been reported in several MPN cases . Also in agreement with previously published data, the CALR positive group had more males (56.8 %) compared to the JAK2 V617F positive group (39.2 %) 9, 12, 13 .
Patients with a CALR mutation also have higher platelet counts 989.8 ± 371.3*10 9 /L versus 863.4 ± 288.4*10 9 /L, p=0.03 (mean ± SD)), lower erythrocyte counts (4.4 ± 0.9*10 12 /L versus 4.9 ± 0.6*10 12 /L, p<0.001), hemoglobin (13.3 ± 1.8 g/dL versus 14.4 ± 1.6 g/dL, p=0.002) and hematocrit (40.2 ± 6.1 % versus 43.9 ± 4.7 %, p<0.001) and lower leukocyte counts (8.9 ± 2.6*10 9 /L versus 11.6 ± 5.9*10 9 /L, p=0.001), ( . Other studies found comparable progression rates to MF in CALR positive and JAK2 V617F positive ET 12, 13, 23 .
86 % of patients in our study group started on cytoreductive therapy, most commonly hydroxyurea, upon their diagnosis. The triple negative group had significantly lower number of treated patients compared to CALR positive and JAK2 V617F positive patients (p=0.04).
ET is associated with cardiovascular complications including stroke, acute coronary syndrome, transient ischemic attack, pulmonary embolism, abdominal thrombosis, deep-vein thrombosis, and peripheral arterial thrombosis. We assessed whether the mutational status was associated with differences in the incidence of cardiovascular complications at diagnosis and arterial thrombosis or venous events. In our cohort of patients the risk of developing any of these complications did not significantly differ between the different molecular subtypes.
We also compared the clinical and hematological data of CALR Type 1 and Type 2 subgroups and compared them to the JAK2 V617F positive group (Supplementary Table 2 ). Remarkably, the male predilection was confined to the group with CALR Type 1 mutations, and this group also had a tendency for the highest platelet counts and is associated with younger age compared to the JAK2 V617F positive group. Tefferi et al. also reported that CALR Type 1 is associated with male gender.
However, they also reported that Type 2 is associated with younger age and higher platelet counts 24 , which was not confirmed in our study nor by another study published by Andrikovics et al. 22 .
We have divided our JAK2 V617F positive group into a group of low mutational load (≤10%; n=11) and high mutational load (>10%; n=46) as determined by quantitative polymerase chain reaction.
However, no significant differences between both groups were revealed (Supplementary Table 3 ).
Given the low number of JAK2 low load patients, this comparison needs to be further tested on larger groups.
The mean follow-up of the CALR positive, the JAK2 V617F positive and the triple negative group was 14, 7, and 7 years and the median overall survival as evaluated by (Figure 2A ). The myelofibrosis-free survival ( Figure 2B ) and leukemia-free survival ( Figure 2C ) were not significantly different between the CALR positive group and the JAK2 V617F positive group (p=0.65, p=0.09). In our study, none of the triple negative patients progressed to MF or AML.
In the first paper by (Figure 3 ). This indicates that the prognosis of CALR/JAK2 mutated ET is different only in younger age groups.
We also describe, what is to the best of our knowledge, the fourth ET patient with both a JAK2 V617F and a CALR mutation. In this patient the JAK2 V617F mutational load assessed by allele specific PCR was around 0.2%, while the mutational load of CALR Type 2 estimated by Sanger sequencing was around 40%. Based on the differential mutational loads two scenarios are possible;
either the JAK2 V617F is a subclonal mutation in the major CALR mutated clone, or the two mutations arose in two different clones with the CALR clone being the largest, with the JAK2 V617F as a minor clone. Given that no viably frozen material is available, this issue can unfortunately not be further investigated in vitro.
In summary, this study of 160 ET patients confirms that CALR positive ET is phenotypically and biologically distinct from the JAK2 V617F positive ET, in terms of clinical presentation and disease evolution. We also observed that CALR mutant ET was associated with better overall survival in younger ET patient groups. Our study also suggests the possibility of phenotypic differences within the CALR mutant group according to the mutation type, in line with a few other studies 22, 24 .
Although the analysis of CALR mutations is rapidly being implemented in the diagnostic work-up of ET, the molecular ET subtypes are, at the time of this writing, not taken into account for treatment decisions in ET.
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